The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone

Introduction The synthetic glucocorticoid dexamethasone can induce serious neuropsychiatric adverse effects. Dexamethasone activates the glucocorticoid receptor (GR) but, unlike endogenous cortisol, not the mineralocorticoid receptor (MR). Moreover, dexamethasone suppresses cortisol production, ther...

Full description

Saved in:
Bibliographic Details
Main Authors: Elisabeth F C van Rossum, Amir H Zamanipoor Najafabadi, Wouter A Moojen, Nienke R Biermasz, Wouter R van Furth, Onno C Meijer, Clemens M F Dirven, Anne-Sophie C A M Koning, Djaina D Satoer, Christiaan H Vinkers, Rishi D S Nandoe Tewarie, Alberto M Pereira
Format: Article
Language:English
Published: BMJ Publishing Group 2021-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/12/e054405.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846128880068329472
author Elisabeth F C van Rossum
Amir H Zamanipoor Najafabadi
Wouter A Moojen
Nienke R Biermasz
Wouter R van Furth
Onno C Meijer
Clemens M F Dirven
Anne-Sophie C A M Koning
Djaina D Satoer
Christiaan H Vinkers
Rishi D S Nandoe Tewarie
Alberto M Pereira
author_facet Elisabeth F C van Rossum
Amir H Zamanipoor Najafabadi
Wouter A Moojen
Nienke R Biermasz
Wouter R van Furth
Onno C Meijer
Clemens M F Dirven
Anne-Sophie C A M Koning
Djaina D Satoer
Christiaan H Vinkers
Rishi D S Nandoe Tewarie
Alberto M Pereira
author_sort Elisabeth F C van Rossum
collection DOAJ
description Introduction The synthetic glucocorticoid dexamethasone can induce serious neuropsychiatric adverse effects. Dexamethasone activates the glucocorticoid receptor (GR) but, unlike endogenous cortisol, not the mineralocorticoid receptor (MR). Moreover, dexamethasone suppresses cortisol production, thereby eliminating its MR binding. Consequently, GR overactivation combined with MR underactivation may contribute to the neuropsychiatric adverse effects of dexamethasone. The DEXA-CORT trial aims to reactivate the MR using cortisol to reduce neuropsychiatric adverse effects of dexamethasone treatment.Methods and analysis The DEXA-CORT study is a multicentre, randomised, double-blind, placebo-controlled trial in adult patients who undergo elective brain tumour resection treated perioperatively with high doses of dexamethasone to minimise cerebral oedema. 180 patients are randomised between treatment with either two times per day 10 mg hydrocortisone or placebo during dexamethasone treatment. The primary study outcome is the difference in proportion of patients scoring ≥3 points on at least one of the Brief Psychiatric Rating Scale (BPRS) questions 5 days postoperatively or earlier at discharge. Secondary outcomes are neuropsychiatric symptoms, quality of sleep, health-related quality of life and neurocognitive functioning at several time points postoperatively. Furthermore, neuropsychiatric history, serious adverse events, prescribed (psychiatric) medication and referrals or evaluations of psychiatrist/psychologist and laboratory measurements are assessed.Ethics and dissemination The study protocol has been approved by the Medical Research Ethics Committee of the Leiden University Medical Center, and by the Dutch competent authority, and by the Institutional Review Boards of the participating sites. It is an investigator-initiated study with financial support by The Netherlands Organisation for Health Research and Development (ZonMw) and the Dutch Brain Foundation. Results of the study will be submitted for publication in a peer-reviewed journal.Trial registration number NL6726 (Netherlands Trial Register); open for patient inclusion. EudraCT number 2017-003705-17.
format Article
id doaj-art-5ade67313dc3462f8dcbaeecd7ae8f8c
institution Kabale University
issn 2044-6055
language English
publishDate 2021-12-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-5ade67313dc3462f8dcbaeecd7ae8f8c2024-12-10T15:25:09ZengBMJ Publishing GroupBMJ Open2044-60552021-12-01111210.1136/bmjopen-2021-054405The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasoneElisabeth F C van Rossum0Amir H Zamanipoor Najafabadi1Wouter A Moojen2Nienke R Biermasz3Wouter R van Furth4Onno C Meijer5Clemens M F Dirven6Anne-Sophie C A M Koning7Djaina D Satoer8Christiaan H Vinkers9Rishi D S Nandoe Tewarie10Alberto M Pereira11Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The NetherlandsDepartment of Neurosurgery, University Neurosurgical Center Holland, Leiden University Medical Center, Haaglanden Medical Center and Haga Teaching Hospitals, Leiden and The Hague, The NetherlandsNeurosurgery, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Medicine, Division of Endocrinology, and Centre for Endocrine Tumors Leiden (CETL), Leiden University Medical Center, Leiden, The NetherlandsDepartment of Neurosurgery, Leiden University Medical Center, Leiden, NetherlandsDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Neurosurgery, Erasmus Medical Center, Rotterdam, The NetherlandsDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands6 Neurosurgery, Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlandsassistant professorDepartment of Neurosurgery, University Neurosurgical Center Holland, Leiden University Medical Center, Haaglanden Medical Center and Haga Teaching Hospitals, Leiden and The Hague, The NetherlandsDepartment of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The NetherlandsIntroduction The synthetic glucocorticoid dexamethasone can induce serious neuropsychiatric adverse effects. Dexamethasone activates the glucocorticoid receptor (GR) but, unlike endogenous cortisol, not the mineralocorticoid receptor (MR). Moreover, dexamethasone suppresses cortisol production, thereby eliminating its MR binding. Consequently, GR overactivation combined with MR underactivation may contribute to the neuropsychiatric adverse effects of dexamethasone. The DEXA-CORT trial aims to reactivate the MR using cortisol to reduce neuropsychiatric adverse effects of dexamethasone treatment.Methods and analysis The DEXA-CORT study is a multicentre, randomised, double-blind, placebo-controlled trial in adult patients who undergo elective brain tumour resection treated perioperatively with high doses of dexamethasone to minimise cerebral oedema. 180 patients are randomised between treatment with either two times per day 10 mg hydrocortisone or placebo during dexamethasone treatment. The primary study outcome is the difference in proportion of patients scoring ≥3 points on at least one of the Brief Psychiatric Rating Scale (BPRS) questions 5 days postoperatively or earlier at discharge. Secondary outcomes are neuropsychiatric symptoms, quality of sleep, health-related quality of life and neurocognitive functioning at several time points postoperatively. Furthermore, neuropsychiatric history, serious adverse events, prescribed (psychiatric) medication and referrals or evaluations of psychiatrist/psychologist and laboratory measurements are assessed.Ethics and dissemination The study protocol has been approved by the Medical Research Ethics Committee of the Leiden University Medical Center, and by the Dutch competent authority, and by the Institutional Review Boards of the participating sites. It is an investigator-initiated study with financial support by The Netherlands Organisation for Health Research and Development (ZonMw) and the Dutch Brain Foundation. Results of the study will be submitted for publication in a peer-reviewed journal.Trial registration number NL6726 (Netherlands Trial Register); open for patient inclusion. EudraCT number 2017-003705-17.https://bmjopen.bmj.com/content/11/12/e054405.full
spellingShingle Elisabeth F C van Rossum
Amir H Zamanipoor Najafabadi
Wouter A Moojen
Nienke R Biermasz
Wouter R van Furth
Onno C Meijer
Clemens M F Dirven
Anne-Sophie C A M Koning
Djaina D Satoer
Christiaan H Vinkers
Rishi D S Nandoe Tewarie
Alberto M Pereira
The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone
BMJ Open
title The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone
title_full The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone
title_fullStr The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone
title_full_unstemmed The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone
title_short The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone
title_sort dexa cort trial study protocol of a randomised placebo controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone
url https://bmjopen.bmj.com/content/11/12/e054405.full
work_keys_str_mv AT elisabethfcvanrossum thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT amirhzamanipoornajafabadi thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT wouteramoojen thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT nienkerbiermasz thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT wouterrvanfurth thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT onnocmeijer thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT clemensmfdirven thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT annesophiecamkoning thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT djainadsatoer thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT christiaanhvinkers thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT rishidsnandoetewarie thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT albertompereira thedexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT elisabethfcvanrossum dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT amirhzamanipoornajafabadi dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT wouteramoojen dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT nienkerbiermasz dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT wouterrvanfurth dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT onnocmeijer dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT clemensmfdirven dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT annesophiecamkoning dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT djainadsatoer dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT christiaanhvinkers dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT rishidsnandoetewarie dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone
AT albertompereira dexacorttrialstudyprotocolofarandomisedplacebocontrolledtrialofhydrocortisoneinpatientswithbraintumouronthepreventionofneuropsychiatricadverseeffectscausedbyperioperativedexamethasone